ΑI)	

Award Number: DAMD17-01-1-0658

TITLE: The Role of AIB1 in Estrogen-dependent Breast Tumor Cell

Growth

PRINCIPAL INVESTIGATOR: Fern E. Murdoch, Ph.D.

CONTRACTING ORGANIZATION:

University of Wisconsin-Madison Madison, Wisconsin 53706-1490

REPORT DATE: July 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030109 064

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blan	k) 2. REPORT DATE	3. REPORT TYPE AND	DATES COVERI	ED
	July 2002	Final (1 Jul 0:		
4. TITLE AND SUBTITLE			5. FUNDING N	
The Role of AIB1 in Estrogen-de	ependent Breast Tumor Cell Grov	vth	DAMD17-01	-1-0658
6. AUTHOR(S)				
I and the second				
Fern E. Murdoch, Pl	n.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PE				G ORGANIZATION
University of Wisco	onsin-Madison		REPORT NUMBER	
Madison, Wisconsin				
	33,00 1430			
E-Mail: femurdoch@facstaff.wisc.edu	1			
	•			
9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRESS(E	S)		NG / MONITORING
IIC Ammu Madical Daniel	136		AGENCY R	EPORT NUMBER
U.S. Army Medical Research and				
Fort Detrick, Maryland 21702-5	012			
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILIT				12b. DISTRIBUTION CODE
Approved for Public Re	lease; Distribution Uni	limited		
	lease; Distribution Uni	limited		
	lease; Distribution Uni	limited		
Approved for Public Re		limited		
Approved for Public Re 13. ABSTRACT (Maximum 200 Wo	rds)		· · · · · · · · · · · · · · · · · · ·	
Approved for Public Re 13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate	<i>rds)</i> or, binds to estrogen re	ceptor (ER) and i	ncreases e	strogen-dependent
Approved for Public Re 13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o	<i>rds)</i> or, binds to estrogen re overexpressed in 64% of	ceptor (ER) and i	mors. We h	strogen-dependent
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr	rds) or, binds to estrogen re overexpressed in 64% of cogen-dependent growth u	ceptor (ER) and i primary breast tu	mors. We h heir trans	strogen-dependent ypothesize that cription. Our
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts tha	rds) or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth uset decreasing AIB1 shoul	ceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge	mors. We h heir trans	strogen-dependent ypothesize that cription. Our
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts tha transcription. Our exp	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth use to decreasing AIB1 should be timental goal was to decrimental goal was to decribe goal was to decribe goal was to decribe goal was to decribe goal goal was to decribe goal was to decribe goal was to decribe goal goal was to decribe goal goal was to decribe goal goal goal goal goal goal goal goal	ceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors	mors. We heir trans n-dependen to AIB1, i	strogen-dependent ypothesize that cription. Our t growth and ntroduce them
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for esta hypothesis predicts tha transcription. Our exp into MCF-7 cells, and a	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth use the decreasing AIB1 should be the column at the colu	ceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone	mors. We heir trans n-dependen to AIB1, i	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PGR) expression
Approved for Public Re 13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth wat decreasing AIB1 should be rimental goal was to decreasely cell proliferations and two types of inhibi	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first	mors. We heir trans n-dependen to AIB1, i receptor was a smal	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth wat decreasing AIB1 should be rimental goal was to decrease cell proliferation and two types of inhibiting acids of the HIV T	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, and	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth was to decreasing AIB1 should be rimental goal was to decrease cell proliferation and two types of inhibiting acids of the HIV Total the 19 amino acids from the strong acids of the 19 amino acids from the strong acids from the strong acids of the HIV Total the 19 amino acids from the strong acids of the strong acids from the strong acids of the strong acids acids of the strong acids acids of the strong acids ac	ceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 tha	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is a genes required for esta hypothesis predicts tha transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide	or, binds to estrogen recoverexpressed in 64% of agen-dependent growth uset decreasing AIB1 should be rimental goal was to decrimental goal was to decrease the say cell proliferation and two types of inhibiting acids of the HIV Total the 19 amino acids free was that this polypep	cceptor (ER) and in primary breast tuntilize AIB1 for the dinhibit estroger design inhibitors and progesterone tors. The first AT protein that he company to the AIB1 LXXLL tide would compet	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous,
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth uset decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibiting and the 19 amino acids free was that this polypepending to ER and thereby ect on estrogen-dependent	cceptor (ER) and in primary breast tuntilize AIB1 for the dinhibit estroged lesign inhibitors and progesterone tors. The first AT protein that how the AIB1 LXXLL tide would compet disrupt function the growth or PgR e	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 tha e with the However xpression.	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth use the decreasing AIB1 should be rimental goal was to decrimental goal was to decribe a was that this polypepending to ER and thereby ect on estrogen-dependences and are stably transfer	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR eecting a second i	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the . However xpression. nhibitor u	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE-
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth uset decreasing AIB1 should be rimental goal was to decrease two types of inhibitions and the 19 amino acids from a was that this polypepending to ER and thereby est and are stably transfall three nuclear receptors of the property of the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three strongen and the stably transfall three strongen and the strongen and t	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR e ecting a second i tor interaction	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the . However xpression. nhibitor uoxes of th	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth uset decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibiting and the 19 amino acids free was that this polypepending to ER and thereby ect on estrogen-dependent	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR e ecting a second i tor interaction	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the . However xpression. nhibitor uoxes of th	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth uset decreasing AIB1 should be rimental goal was to decrease two types of inhibitions and the 19 amino acids from a was that this polypepending to ER and thereby est and are stably transfall three nuclear receptors of the property of the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three strongen and the stably transfall three strongen and the strongen and t	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR e ecting a second i tor interaction	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the . However xpression. nhibitor uoxes of th	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent o inhibitor.	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth uset decreasing AIB1 should be rimental goal was to decrease two types of inhibitions and the 19 amino acids from a was that this polypepending to ER and thereby est and are stably transfall three nuclear receptors of the property of the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three nuclear receptors of the strongen and the stably transfall three strongen and the stably transfall three strongen and the strongen and t	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR e ecting a second i tor interaction	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the However xpression. nhibitor u oxes of th re not yet	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects known for this
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent o inhibitor.	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth wat decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibit and the 19 amino acids from a was that this polypept and to ER and thereby est on estrogen-dependents and are stably transfall three nuclear receptors.	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR e ecting a second i tor interaction b in these cells a	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the However xpression. nhibitor u oxes of th re not yet	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects known for this
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent o inhibitor.	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth wat decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibit and the 19 amino acids from a was that this polypept and to ER and thereby est on estrogen-dependents and are stably transfall three nuclear receptors.	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR e ecting a second i tor interaction b in these cells a	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the However xpression. nhibitor u oxes of th re not yet	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects known for this
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of inhibitor. 14. SUBJECT TERMS breast cancer, estrogen	or, binds to estrogen representation of the state of the	cceptor (ER) and in primary breast tustilize AIB1 for the dinhibit estroger lesign inhibitors and progesterone tors. The first AT protein that how the AIB1 LXXLL tide would competed disrupt function the growth or PgR effecting a second in these cells and to interaction be in these cells and to inhibitor	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the . However xpression. nhibitor u oxes of the not yet	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects known for this
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of inhibitor. 14. SUBJECT TERMS breast cancer, estroger	or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth wat decreasing AIB1 should be estimental goal was to decrease the compact of the HIV To the HIV To the compact of the HIV To the compact of the HIV To the HIV To the compact of the HIV To THE COMPACT OF THE HIV TO THE COMPACT OF THE COMPACT	cceptor (ER) and i primary breast tu tilize AIB1 for t d inhibit estroge esign inhibitors and progesterone tors. The first AT protein that h om the AIB1 LXXLL tide would compet disrupt function t growth or PgR e ecting a second i tor interaction b in these cells a for interaction brown the cells a for inhibitor	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the . However xpression. nhibitor u oxes of the not yet	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects known for this
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of inhibitor. 14. SUBJECT TERMS breast cancer, estrogen	or, binds to estrogen representation of the state of the	cceptor (ER) and in primary breast tustilize AIB1 for the dinhibit estroger lesign inhibitors and progesterone tors. The first AT protein that how the AIB1 LXXLL tide would competed disrupt function the growth or PgR effecting a second in these cells and to interaction be in these cells and to inhibitor	mors. We heir trans n-dependen to AIB1, i receptor was a smal ave been s box 2 that e with the . However xpression. nhibitor u oxes of the not yet	strogen-dependent ypothesize that cription. Our t growth and ntroduce them (PgR) expression l polypeptide hown to transduce t has been shown endogenous, , this We have created nder a TRE- e AIB1. Affects known for this

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	4
Key Research Accomplishments	5
Reportable Outcomes	5
Conclusions	6
References	6
Appendices	none

INTRODUCTION

AIB1, a p160 coactivator, binds to estrogen receptor (ER) and increases estrogendependent transcription. It is overexpressed in 64% of primary breast tumors. We hypothesize that genes required for estrogen-dependent growth utilize AIB1 for their transcription. Our hypothesis predicts that decreasing AIB1 should inhibit estrogendependent growth and transcription. Our experimental goal was to design inhibitors to AIB1, introduce them into MCF-7 cells, and assay cell proliferation and progesterone receptor (PgR) expression as end-points. We designed two types of inhibitors. The first was a small polypeptide that contained the 11 amino acids of the HIV TAT protein that have been shown to transduce proteins into cells, and the 19 amino acids from the AIB1 LXXLL box 2 that has been shown to bind to ER. The idea was that this polypeptide would compete with the endogenous, full-length AIB1 for binding to ER and thereby disrupt function. However, this polypeptide had no affect on estrogen-dependent growth or PgR expression. We have created MCF-7 Tet-Off cell lines and are stably transfecting a second inhibitor under a TRE-promoter that contains all three nuclear receptor interaction boxes of the AIB1. Affects on estrogen-dependent growth and transcription in these cells are not yet known for this inhibitor.

BODY

Our goal was to inhibit AIB1 function in MCF-7 cells to determine if this protein was required for estrogen-dependent cell growth or gene expression.

The first inhibitor we designed was to take advantage of the transduction sequence found in the HIV TAT protein. This small, 11 amino acid sequence, can transduce polypeptides into almost any cell type. Such an inhibitor would be quite versatile. We selected the box 2 LXXLL region of the AIB1 protein to add to the TAT sequence. We chose this fragment of AIB1, because it has the highest binding affinity for ER (1). The total peptide was

YGRKKRRQRRRGQEKHRILHHKLLQNGNSPAE.

This peptide was chemically synthesized and added to the culture media of MCF-7 cells at a final concentration of up to 10 micromolar. Cells were treated with and without 1 nM estradiol and assayed for growth rate and progesterone receptor expression. Estradiol increased the doubling time of the cells from 350 hours to 67 hours in withdrawal media. Addition of the peptide had no affect on this doubling rate. The expression of progesterone receptor was assayed by whole cell uptake assays and western blot. Estradiol strongly induced expression of both isoforms of this protein from undetectable levels in withdrawal media over three days. Addition of the peptide had no affect on this doubling rate.

We verified the functionality of the peptide by assaying for the estradiol dissociation rate from estrogen receptor. Bound peptide was expected to substantially decrease the ligand dissociation rate since it stabilizes helix 12 in a conformation that covers the ligand binding pocket of ER (2). Our peptide had a dramatic effect on the dissociation of 3H-estradiol from the ER protein. The t(1/2) for estradiol on the ER was 34 minutes and was increased to 216 minutes in the presence of 10 micromolar peptide.

Using this assay we determined that the approximate binding affinity of our peptide to the ER in vitro was about 3 micromolar. Our failure to observe any effects of this peptide on estrogen-induced growth and transcription in our MCF-7 cells could be due to several problems; 1) failure to achieve a sufficiently high concentration, 2) degradation of the peptide in the cells, 3) failure of the peptide to localize to the nucleus. We chose a design for a second inhibitor that would address these potential problems.

The second AIB1 inhibitor we have constructed contains the fragment of the AIB1 cDNA from #1965-2489 (175 amino acids) that contains all three receptor interaction domains with LXXLL motifs, but none of the activation domains. The construct also contains the SV40 large T antigen nuclear localization signal, 2 HA antigen tags, and a Kozak sequence for efficient translation. Upon translation this construct will yield a 23Kd protein that will localize to the nucleus and efficiently bind the ER. We have constructed Tet-Off MCF-7 cell lines and are in the process of stably transfecting our construct into these cells under a TRE containing promoter. We chose this design to achieve the highest possible expression of the inhibitor without adding tetracycline to the media. Addition of tetracycline should inhibit expression of the inhibitor. Our future plans are to assay these stable cell lines for estrogen-dependent growth and gene expression in the presence and absence of tetracycline. We will be able to quantitate the expression of our inhibitor by Western blot for the HA tags and verify its nuclear localization by immunocytochemistry for the HA tags.

KEY RESEARCH ACCOMPLISHMENTS

- Characterization of TAT-LXXLL polypeptide as a potential inhibitor of ER-AIB1 interaction in vivo. Functioned to inhibit ligand dissociation in vitro, but did not affect ER function in MCF-7 cells.
- Derived and characterized MCF-7 cell lines stably expressing Tet-Off transcription factor. Cells lines were characterized for estrogen-induced growth and ERE-luciferase expression.
- Construction of construct for stable, repressible expression in MCF-7 cells of a second potential ER-AIB1 interaction inhibitor. Construct contains the receptor interaction domains of the AIB1 protein, 2 HA-tags, nuclear localization signal.

REPORTABLE OUTCOMES

- Development of Tet-off MCF-7 cell lines
- Construction of potential inhibitor of ER-AIB1 interactions

CONCLUSIONS

The development of molecule that can disrupt ER-AIB1 interactions will provide a critical tool to dissect the estrogen-induced pathways that are dependent on this interaction. We have determined that he use of a TAT-peptide is not effective in our system, probably due to the limited concentrations we can achieve in the cell over time. We have turned our efforts to a stable expression system.

REFERENCES

- 1. Gee AC, Carlson KE, Martini PG, Katzenellenbogen BS, and Katzenellenbogen JA (1999) Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol. Endocrinol. 13:1912-23.
- 2. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, and Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-37.

PERSONEL

Carley Sauter Timothy Kruser Amy Stoddard Brittany Conrad